147 related articles for article (PubMed ID: 1970151)
1. Anti-receptor antibodies reverse the phenotype of cells transformed by two interacting proto-oncogene encoded receptor proteins.
Wada T; Myers JN; Kokai Y; Brown VI; Hamuro J; LeVea CM; Greene MI
Oncogene; 1990 Apr; 5(4):489-95. PubMed ID: 1970151
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor-alpha expression is enhanced in human mammary epithelial cells transformed by an activated c-Ha-ras protooncogene but not by the c-neu protooncogene, and overexpression of the transforming growth factor-alpha complementary DNA leads to transformation.
Ciardiello F; McGeady ML; Kim N; Basolo F; Hynes N; Langton BC; Yokozaki H; Saeki T; Elliott JW; Masui H
Cell Growth Differ; 1990 Sep; 1(9):407-20. PubMed ID: 1981145
[TBL] [Abstract][Full Text] [Related]
3. The role of the neu oncogene product in cell transformation and normal development.
Kokai Y; Wada T; Myers JN; Brown VI; Dobashi K; Cohen J; Hamuro J; Weiner DB; Greene MI
Princess Takamatsu Symp; 1988; 19():45-57. PubMed ID: 2908355
[TBL] [Abstract][Full Text] [Related]
4. Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy.
Dougall WC; Qian X; Greene MI
J Cell Biochem; 1993 Sep; 53(1):61-73. PubMed ID: 7901229
[TBL] [Abstract][Full Text] [Related]
5. Constitutively activated neu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation.
Lehtola L; Sistonen L; Koskinen P; Lehväslaiho H; Di Renzo MF; Comoglio PM; Alitalo K
J Cell Biochem; 1991 Jan; 45(1):69-81. PubMed ID: 1706346
[TBL] [Abstract][Full Text] [Related]
6. Activation of an EGFR/neu chimeric receptor: early intracellular signals and cell proliferation responses.
Pandiella A; Lehvaslaiho H; Magni M; Alitalo K; Meldolesi J
Oncogene; 1989 Nov; 4(11):1299-305. PubMed ID: 2573029
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
Drebin JA; Link VC; Greene MI
Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
[TBL] [Abstract][Full Text] [Related]
8. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation.
Qian X; Dougall WC; Hellman ME; Greene MI
Oncogene; 1994 May; 9(5):1507-14. PubMed ID: 7908733
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of specific protein tyrosine phosphatases in human breast epithelial cells neoplastically transformed by the neu oncogene.
Zhai YF; Beittenmiller H; Wang B; Gould MN; Oakley C; Esselman WJ; Welsch CW
Cancer Res; 1993 May; 53(10 Suppl):2272-8. PubMed ID: 8097963
[TBL] [Abstract][Full Text] [Related]
10. Neu and its ligands: from an oncogene to neural factors.
Peles E; Yarden Y
Bioessays; 1993 Dec; 15(12):815-24. PubMed ID: 7908191
[TBL] [Abstract][Full Text] [Related]
11. Similar early gene responses to ligand-activated EGFR and neu tyrosine kinases in NIH3T3 cells.
Koskinen P; Lehväslaiho H; MacDonald-Bravo H; Alitalo K; Bravo R
Oncogene; 1990 Apr; 5(4):615-8. PubMed ID: 1970155
[TBL] [Abstract][Full Text] [Related]
12. Analysis of mammalian fibroblast transformation by normal and mutated human EGF receptors.
Haley JD; Hsuan JJ; Waterfield MD
Oncogene; 1989 Mar; 4(3):273-83. PubMed ID: 2784850
[TBL] [Abstract][Full Text] [Related]
13. Regulation by EGF is maintained in an overexpressed chimeric EGFR/neu receptor tyrosine kinase.
Lehväslaiho H; Sistonen L; diRenzo F; Partanen J; Comoglio P; Hölttä E; Alitalo K
J Cell Biochem; 1990 Mar; 42(3):123-33. PubMed ID: 1969420
[TBL] [Abstract][Full Text] [Related]
14. ras and neu oncogenes reverse serum inhibition and epidermal growth factor dependence of serum-free mouse embryo cells.
Shirahata S; Rawson C; Loo D; Chang YJ; Barnes D
J Cell Physiol; 1990 Jul; 144(1):69-76. PubMed ID: 1973170
[TBL] [Abstract][Full Text] [Related]
15. Acquisition of a tumorigenic phenotype by a rat ventral prostate epithelial cell line expressing a transfected activated neu oncogene.
Sikes RA; Chung LW
Cancer Res; 1992 Jun; 52(11):3174-81. PubMed ID: 1350510
[TBL] [Abstract][Full Text] [Related]
16. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Fan Z; Masui H; Altas I; Mendelsohn J
Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
[TBL] [Abstract][Full Text] [Related]
17. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor.
Chazin VR; Kaleko M; Miller AD; Slamon DJ
Oncogene; 1992 Sep; 7(9):1859-66. PubMed ID: 1354348
[TBL] [Abstract][Full Text] [Related]
18. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties.
Yu D; Wang SS; Dulski KM; Tsai CM; Nicolson GL; Hung MC
Cancer Res; 1994 Jun; 54(12):3260-6. PubMed ID: 7911396
[TBL] [Abstract][Full Text] [Related]
19. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies.
Dougall WC; Qian X; Peterson NC; Miller MJ; Samanta A; Greene MI
Oncogene; 1994 Aug; 9(8):2109-23. PubMed ID: 7913542
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of the early genomic growth factor response in neu oncogene-transformed cells.
Sistonen L; Koskinen PJ; Lehväslaiho H; Lehtola L; Bravo R; Alitalo K
Oncogene; 1990 Jun; 5(6):815-21. PubMed ID: 1972791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
